These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 26634478

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation.
    Argudo A, González de Aledo JM, Alía P, Ramírez P, Serrano T, Fabregat J, Castellote J.
    Transplant Proc; 2015 Oct; 47(8):2388-92. PubMed ID: 26518936
    [Abstract] [Full Text] [Related]

  • 4. Effects of donor-recipient combinational CYP3A5 genotypes on tacrolimus dosing in Chinese DDLT adult recipients.
    Liu J, Chen D, Yao B, Guan G, Liu C, Jin X, Wang X, Liu P, Sun Y, Zang Y.
    Int Immunopharmacol; 2020 Mar; 80():106188. PubMed ID: 31931373
    [Abstract] [Full Text] [Related]

  • 5. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.
    Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, Vizzini G, Salis P, Caccamo C, Bertani T, Palazzo U, Polidori P, Gridelli B, D'Alessandro N.
    Int J Mol Med; 2011 Dec; 28(6):1093-102. PubMed ID: 21922127
    [Abstract] [Full Text] [Related]

  • 6. Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period.
    Zhang X, Wang Z, Fan J, Liu G, Peng Z.
    Eur J Clin Pharmacol; 2011 Aug; 67(8):803-13. PubMed ID: 21359536
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
    Shi Y, Li Y, Tang J, Zhang J, Zou Y, Cai B, Wang L.
    Gene; 2013 Jan 10; 512(2):226-31. PubMed ID: 23107770
    [Abstract] [Full Text] [Related]

  • 10. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
    Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, Tanaka K, Inui K.
    Pharmacogenetics; 2004 Jul 10; 14(7):471-8. PubMed ID: 15226679
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus.
    Li D, Zhu JY, Gao J, Wang X, Lou YQ, Zhang GL.
    Clin Chim Acta; 2007 Aug 10; 383(1-2):133-9. PubMed ID: 17568575
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients.
    Gómez-Bravo MA, Apellaniz-Ruiz M, Salcedo M, Fondevila C, Suarez F, Castellote J, Rufian S, Pons JA, Bilbao I, Alamo JM, Millán O, Brunet M, Rodríguez-Antona C.
    Pharmacogenet Genomics; 2018 Feb 10; 28(2):41-48. PubMed ID: 29256966
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.